Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer

BMC Cancer

Table 2 Intracranial efficacy sesults

Variable	Icotinib (n = 21)		Gefitinib (n = 22)		P value
Variable	No.	%	No.	%
Intracranial response
CR (%)	3	14.3	3	13.6
PR (%)	11	52.3	10	45.5
SD (%)	4	19.1	5	22.7
PD (%)	2	9.5	2	9.1
NA (%)	1	4.8	2	9.1
Intracranial RR, %	66.6.		59.1		0.62
95% CI	44.7 to 88.6		36.8 to 81.4
Intracranial DCR, %	85.7		81.8
95% CI	69.4 to 100		64.3 to 99.3		0.73
Median iPFS (months)	8.4		10.6		0.2
95% CI	5.4 to 11.3		6.3 to 14.8

Abbreviations: CR complete remission, PR partial remission, SD stable disease, PD progression disease, NA not assessed, RR response rate, DCR disease control rate

ISSN: 1471-2407